Key result
Screening for subclinical atherosclerosis using carotid intima-media thickness and coronary artery calcium scoring has promising prognostic value in patients with metabolic syndrome.
Why the study?
Does screening for subclinical atherosclerosis improve risk stratification in patients with metabolic syndrome?
Does screening for subclinical atherosclerosis improve risk stratification in patients with metabolic syndrome?
Screening for subclinical atherosclerosis with CIMT and CAC scoring may improve risk stratification and clinical outcomes in patients with metabolic syndrome.
May aid risk stratification in metabolic syndrome; leaves open need for prospective outcome trials before clinical adoption.
The metabolic syndrome is a clustering of risk factors known to promote or increase the risk of diabetes development and subsequent cardiovascular disease. Screening for subclinical atherosclerosis using new imaging technologies or novel biomarkers could help to further risk-stratify patients with metabolic syndrome. In particular, noninvasive imaging of carotid intima-media thickness and coronary artery calcium scoring seem to have promising prognostic value in identifying patients at high risk. Early identification could lead to improved patient or physician adherence to risk-reducing behaviors or interventions and improve clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Malik et al. (2009) conducted a review in Metabolic syndrome. Screening for subclinical atherosclerosis was evaluated. Screening for subclinical atherosclerosis using carotid intima-media thickness and coronary artery calcium scoring has promising prognostic value in patients with metabolic syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: